Visum Prius Ltd.

To study the pharmacokinetic characteristics of a single oral administration of trazodone hydrochloride sustained-release tablets (test preparation, specification: 75 mg) provided by Huayi Taikang Pharmaceutical Co., Ltd. under fasting conditions in healthy subjects and a single oral administration of trazodone hydrochloride sustained-release tablets (reference preparation, trade name: Trittico®, specification: 75 mg) certified by AZ. Chim. Riun. Angelini Francesco Acraf S.P.A. under the same conditions, to evaluate the bioequivalence between the two preparations and provide a basis for the registration application of the test preparation.

To study the pharmacokinetic characteristics of a single oral administration of trazodone hydrochloride sustained-release tablets (test preparation, specification: 75 mg) provided by Huayi Taikang Pharmaceutical Co., Ltd. under postprandial conditions in healthy subjects and a single oral administration of trazodone hydrochloride sustained-release tablets (reference preparation, trade name: Trittico®, specification: 75 mg) certified by AZ. Chim. Riun. Angelini Francesco Acraf S.P.A. under the same conditions, to evaluate the bioequivalence between the two preparations and provide a basis for the registration application of the test preparation.

To investigate the pharmacokinetic characteristics of healthy study participants after a single oral administration of mycophenolate sodium enteric-coated tablets (test preparation, specification: 0.18g) provided by Huayi Taikang Pharmaceutical Co., Ltd. and a single oral administration of mycophenolate sodium enteric-coated tablets (reference preparation, trade name: Myfortic®, specification: 180mg) certified by Novartis Pharma GmbH under fasting conditions, to evaluate the bioequivalence and safety of the two preparations, and to provide a basis for the registration application of the test preparation.